Lumbrokinase

Enzyme Supplement

Earthworm-derived mixtures of fibrinolytic enzymes sold for cardiovascular support. Available literature is predominantly animal, in vitro, or production research and does not establish clinical benefit or generic oral-product equivalence.

Pharmacokinetic model

A route-level PK model for lumbrokinase is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Enzyme Supplement
Suggested cadence: once daily

Research behind this entry

Recombinant protein production of earthworm lumbrokinase for potential antithrombotic application Wang KY, Tull L, Cooper E, Wang N, Liu D · Evidence-Based Complementary and Alternative Medicine, 2013 DOI
Review of recombinant production approaches and laboratory fibrinolytic properties. It does not provide controlled human efficacy or validate the oral pharmacokinetics of commercial earthworm extracts.
Sirt1 Activation by Post-ischemic Treatment With Lumbrokinase Protects Against Myocardial Ischemia-Reperfusion Injury Wang YH, Li SA, Huang CH, Su HH, Chen YH, Chang JT, Huang SS · Frontiers in Pharmacology, 2018 DOI
Rat ischemia-reperfusion experiment reported favorable cardiac and molecular changes after lumbrokinase. The animal model does not establish preventive cardiovascular benefit in people.

2 published studies referenced in the app, each with a plain-language summary.